| abstract |
The present invention provides compounds of formula (I) wherein R 1 is formula (A) or is phenyl, pyridinyl or pyridazinyl, wherein phenyl, pyridinyl and pyridazinyl are optionally substituted by cyano, lower alkyl, halogen substituted Phenyl, lower alkyl substituted [1,2,4] oxadiazol-3-yl or substituted with 2-oxo-piperidin-1-yl; X is NR or O; R is -C (O) -lower alkyl, -C (O) -cycloalkyl substituted with lower alkyl, cycloalkyl, or phenyl, pyridinyl or pyridazinyl, where phenyl, pyridinyl and pyridazinyl are lower In case of alkyl, lower alkoxy, cyano, -C (O) -lower alkyl, halogen or lower alkyl substituted with halogen R 2 is hydrogen or lower alkyl; R 3 is hydrogen, halogen, cyano, lower alkyl or lower alkyl substituted with halogen; R 4 is hydrogen or lower alkyl Where R 2 and R 4 are not simultaneously hydrogen or lower alkyl; R 5 is lower alkyl; R 6 is substituted with halogen, hydroxy, lower alkyl, lower alkoxy, halogen. The lower alkyl, S (O) 2 -lower alkyl or cyano]; or a pharmaceutically suitable acid addition salt thereof. The compounds of the present invention are highly potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD) It was found. |